Skip to main content

Table 1 Descriptive characteristics of the analysis sample at inclusion and over follow-up, MEMENTO cohort, France, 2011-2019 (N=2186)

From: Disease progression model anchored around clinical diagnosis in longitudinal cohorts: example of Alzheimer’s disease and related dementia

 

Inclusion in the study

Follow-up

Variable

Mean/n

SD/%

N

Repeated measures

N\(^*\)

Individuals characteristics

     Age (years)

70.9

8.7

2186

  

     Female

1349

61.7%

2186

  

     >12 years education

856

39.2%

2186

  

     APOE4 carrier

654

29.9%

2186

  

     CDR sum of the boxes

         = 0

784

35.9%

2186

  

         = 0.5

794

36.3%

2186

  

         = 1

323

14.8%

2186

  

         > 1

285

13.0%

2186

  

Markers of AD (CSF)

     t-tau (pg/ml)

376.0

264.8

341

1.3

395

     p-tau (pg/ml)

62.6

29.5

342

1.3

396

     A\(\beta _{42}\) (pg/ml)

1096.2

411.2

342

1.3

396

Brain imaging markers

     WMH volume (mm3)

9.9

13.2

1993

1.7

2056

     Hippocampal volume (cm3)

6.5

1.3

2047

1.7

2048

     Entorhinal cortex (mm)

3.3

0.4

2041

1.7

2057

     Middle temporal cortex (mm)

2.7

0.1

2047

1.7

2064

     Fusiform cortex (mm)

2.6

0.1

2047

1.7

2064

     PET-FDG (SUVr)

2.1

0.3

1236

1.5

1400

Cognitive tests

     Verbal Fluency (animals cited)

28.3

8.8

2147

4.6

2164

     TMT-A (good moves/sec)

0.6

0.2

2165

4.6

2184

     Free recalls FCSRT (sum score)

26.1

8.3

2169

4.5

2176

  1. SD standard deviation, APOE4 allele \(\epsilon\)4 of the apoliprotein E gene, CDR clinical dementia rating, AD Alzheimer’s disease, CSF cerebrospinal fluid, t-tau total tau, p-tau phosphorylated tau, A\(\beta _{42}\) isoform 42 of protein amyloid, WMH white matter hyperintensities, PET positron emission tomography, FDG fluorodeoxyglucose, SUVr standard uptake value ratio, TMT-A trail making test A, FCSRT free and cued selective reminding test